Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Heidelberg Pharma AG    WL6   DE000A11QVV0

HEIDELBERG PHARMA AG (WL6)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
2.99(c) 2.94(c) 2.91(c) 2.96(c) 2.82 Last
106 580 84 495 10 034 2 795 31 304 Volume
-3.55% -1.67% -1.02% +1.72% -4.73% Change
More quotes
Financials (EUR)
Sales 2018 3,97 M
EBIT 2018 -12,9 M
Net income 2018 -13,0 M
Finance 2018 25,1 M
Yield 2018 -
Sales 2019 4,20 M
EBIT 2019 -11,4 M
Net income 2019 -11,5 M
Finance 2019 13,8 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 14,7x
EV / Sales2019 16,5x
Capitalization 83,3 M
More Financials
Company
Heidelberg Pharma AG engages in the development of diagnostic and therapeutic products for the detection and targeted treatment of various types of cancer.It operates through the following segments: Customer Specific Research (Cx), Diagnostics (Dx) and Therapeutics (Rx).The Customer Specific... 
Sector
Biotechnology & Medical Research
Calendar
06/26 | 11:00amShareholder meeting
More about the company
Surperformance© ratings of Heidelberg Pharma AG
Trading Rating : Investor Rating :
More Ratings
Latest news on HEIDELBERG PHARMA AG
04/12HEIDELBERG PHARMA AG : Interim Management Statement on the First Three Months of..
EQ
04/09HEIDELBERG PHARMA : Presents Proprietary ATAC Technology Platform at Two Scienti..
EQ
03/29HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
03/22HEIDELBERG PHARMA AG : Heidelberg Pharma announces financial figures for fiscal ..
EQ
03/19HEIDELBERG PHARMA AG : annual earnings release
03/15HEIDELBERG PHARMA : Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Mu..
AQ
03/05HEIDELBERG PHARMA AG : Heidelberg Pharma and Magenta Therapeutics Sign Exclusive..
EQ
03/05HEIDELBERG PHARMA AG : Heidelberg Pharma and Magenta Therapeutics Sign Exclusive..
EQ
03/01HEIDELBERG PHARMA : Signs License Agreement with The University of Texas MD Ande..
EQ
02/28HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
2017WILEX AG successfully completes change of name to Heidelberg Pharma AG  
2017WILEX AG: Interim management statement for the first nine months of 2017  
2017WILEX AG: Interim management statement for the first nine months of 2017  
2017WILEX AG: Interim management statement for the first nine months of 2017  
2017WILEX : Announces Adjustment of Guidance  
More tweets
Qtime:25
News from SeekingAlpha
2016Deal Flurry Shines Spotlight On Novel Multiple Myeloma Target 
Chart HEIDELBERG PHARMA AG
Duration : Period :
Heidelberg Pharma AG Technical Analysis Chart | WL6 | DE000A11QVV0 | 4-Traders
Technical analysis trends HEIDELBERG PHARMA AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 4,25 €
Spread / Average Target 44%
EPS Revisions
Managers
NameTitle
Jan Schmidt-Brand Chief Executive & Financial Officer
Christof Hettich Chairman-Supervisory Board
Andreas Pahl Head-Research & Development
Friedrich von Bohlen und Halbach Member-Supervisory Board
Georg F. Baur Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
HEIDELBERG PHARMA AG-8.90%102
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.75%14 493
NEKTAR THERAPEUTICS44.36%13 873